Medical

Opiant Pharmaceuticals said that it has received an additional $2.1 million from the US Biomedical Advanced Research and Development Authority (BARDA) to support regulatory activities related to its OPNT003 intranasal nalmefene for the treatment of opioid overdose. BARDA had… Read more . . .

Verona Pharma said that the Phase 3 ENHANCE-2 trial of nebulized ensifentrine for treatment of COPD met its primary endpoint, with an average change from baseline in FEV1 AUC, 0-12 hours post dose, of 94… Read more . . .

Krystal Biotech said that the FDA has cleared an IND submitted by the company at the beginning of July 2022 and that it now intends to initiate a Phase 1 trial of its KB407 nebulized… Read more . . .

ACM Biolabs has announced the initiation of a Phase 1 trial of its ACM-001 vaccine candidate against SARS-CoV-2. The SAD study will compare ACM-001 to an intramuscular vaccine as a booster in 80 healthy adults… Read more . . .

InCarda Therapeutics has announced the initiation of the Phase 3 RESTORE-1 trial of its InRhythm flecainide inhalation solution in patients with new or recurrent atrial fibrillation. According to InCarda, the FDA has agreed that the… Read more . . .

Revelation Biosciences announced that the Phase 1b CLEAR challenge study of its REVTx-99b intranasal phosphorylated hexaacylated disaccharide (PHAD) in participants with allergies to rye grass pollen showed that the nasal drops were safe and well… Read more . . .

VistaGen Therapeutics said that the PALISADE-1 Phase 3 clinical trial of PH94B aloradine nasal spray for the treatment of anxiety in social anxiety disorder failed to meet its primary endpoint. The company announced the initiation… Read more . . .

CyanVac subsidiary Blue Lake Biotechnology said that dosing has begun in a Phase 1 clinical trial of the company’s BLB-201 intranasal vaccine against respiratory syncytial virus. The open label trial is expected to enroll 15… Read more . . .